Guerrini, C. J. et. al. (2017) Nature Biotechnology. 35:22-24. https://www.ncbi.nlm.nih.gov/pubmed/28072792
While countries and institutions can be slow to adapt to new ethics concerns, patent holders have the ability to restrict use on new technology. The Broad Institute has adopted this method to control uses of the CRISPR/Cas9 technology in licenses with both Monsanto and Editas Medicine. Similarly, the creator of the CRISPR/Cas gene drive plans to use his patent to force full disclosure of methods and results from both academics and industry. While the use of patents to limit ethics concerns is not without problems, it can allow time for larger ethics structures to be implemented.